Advanced search
Enter a research title, an expert name, a programme code such as ADSTEM, or a patent number such as 10-1172638. Results appear as cards with source links you can check yourself.
28 records for “RASTEM”
Each record states the study stage, institution and source link.
preclinical · 2024
EHL BIO (Korea)
The hospital's affiliated research centre states the non-clinical study is being completed and a clinical trial is in preparation. No human outcome data exist; patients should follow standard care such as methotrexate and biologics as prescribed.
EHL BIO (research page)phase2 · 2025
Multiple institutions (indexed in PubMed)
The most advanced research is in graft-versus-host disease, lupus nephritis and fistulising Crohn's disease. Where products are approved, indications are very narrow.
ClinicalTrials.govreview · 2024
Multiple institutions (indexed in PubMed)
Multiple studies report short- to medium-term improvement in pain and function; evidence of cartilage regeneration remains limited and methods vary widely.
PubMedphase1-2 · 2025
International trial registries
Primary endpoints are safety; some studies report more stable insulin requirement and C-peptide over short follow-up, with no conclusions on long-term effect.
ClinicalTrials.govphase1-2 · 2025
Specialised research centres in Japan and the United States
Reports procedural safety and graft survival in small numbers of participants; motor outcomes require long-term follow-up.
ClinicalTrials.govphase2 · 2024
Multiple institutions (indexed in PubMed)
Some studies report improved albumin and MELD scores over 6–12 months; results are inconsistent between studies and standard care is unchanged.
PubMedreview · 2023
Multiple institutions (indexed in PubMed)
Effects on ejection fraction are small and inconsistent, with no clear mortality benefit in large trials.
PubMedphase1-2 · 2024
International trial registries
Reported as well tolerated short term with reductions in some inflammatory markers; no confirmed significant change in lung function.
ClinicalTrials.govphase1-2 · 2024
Multiple institutions (indexed in PubMed)
Small studies report reduced severity scores in some patients; better-controlled studies are needed for confirmation.
PubMedphase1 · 2024
International trial registries
Focused on safety and eGFR decline in small numbers of participants; no evidence of nephron regeneration.
ClinicalTrials.govreview · 2026
EHL BIO (Republic of Korea)
EHL BIO publishes a list of patents and research papers in the R&D section of its corporate website. Readers should verify the current list at the source before citing.
EHL BIO — Patents and Research Papersreview · 2026
EHL BIO (Republic of Korea)
Company public information describes the manufacturing centre, quality systems and cell handling processes. Certifications and current status should be verified at the source.
EHL BIO — GMP centerTitles listed on EHL BIO's research institute page, with PubMed lookup links.
19 Nov 2016
6 Nov 2018
30 Apr 2022
21 Dec 2022
10 Dec 2023
A patent evidences intellectual-property registration, not treatment efficacy.
No. 10-2018-0001149
Registered 4 Jan 2018
Same family of pharmaceutical composition, with the indication stated as rheumatoid arthritis.
EHL BIO patent pageNo. 10-2016-0007049
Registered 20 Jan 2016
Intended to facilitate fat collection and the series of processes for separating adipose-derived stem cells.
EHL BIO patent pageNumber not stated
Registered 28 Dec 2018
Related to a composition comprising cells treated with a 15-PGDH inhibitor or their culture and its use.
EHL BIO patent pageNo. 10-2019-0139702
Registered 4 Nov 2019
Culture medium for isolating and culturing urine-derived stem cells, and a method for separating and culturing them using that medium.
EHL BIO patent pageNo. 10-2020-0012437
Registered 3 Feb 2020
Mass culture method for adipose-derived stem cells expressing Foxo1, Foxo3a and Klotho, with a medium composition for their proliferation and culture.
EHL BIO patent pageNo. 10-2021-0021026
Registered 17 Feb 2021
Cosmetic or pharmaceutical composition with urine-derived stem cell exosomes as the active ingredient.
EHL BIO patent pageNo. 10-2021-0129299
Registered 29 Sept 2021
Covers the culture medium, the isolation and culture method, the resulting cells, and a cell therapeutic composition comprising them.
EHL BIO patent pagePublished profiles contain only details checkable against public sources.
EHL BIO
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentEHL BIO
Chief Executive Officer, EHLBIO Co., Ltd.
Direction of stem cell, immune cell and exosome therapeutics development
EHL BIO — CEO MessageEHL BIO
Manufacturing, quality control and cell banking
Class 100 clean facilities, cell banking systems and pre/post-cryopreservation quality control
EHL BIO — GMP centerEHL Thailand
Writes and reviews disease pages and stem cell topics
Evidence levels, regulatory status, and separating hospital information from medical information
An EHL doctor or scientist? Submit your real biography and licence for the register.
Submit expert profile